Latest Commercial Partnerships News

Blue Star Helium has secured an extension of its helium offtake agreement at the Pinon Canyon Plant through March 2027, ensuring steady revenue while negotiating longer-term contracts.

Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.

Micro-X Limited lifted revenues by 16% to $15.1 million for FY26 but posted a $9.9 million net loss, narrowing from the prior year. The company advanced key medical imaging milestones and initiated a strategic reset to sharpen commercial focus and reduce costs.

Helloworld Travel (ASX:HLO) is rapidly expanding its Australian retail footprint with 14 new stores opened or committed in the past 18 months, alongside the full acquisition of Mobile Travel Agents (MTA), Australia's largest home-based travel network. This growth underscores strong confidence in the Helloworld brand and the enduring demand for expert travel advice.

Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.

Tungsten Mining has engaged Cutfield Freeman to lead debt financing efforts for its Watershed Tungsten Project, following a robust Preliminary Economic Evaluation and targeting a Final Investment Decision in September 2026.

Li-S Energy reported a reduced net loss of $4.9 million in FY26, propelled by major technological advances and a $7.8 million ARENA grant to scale manufacturing. The company secured key regulatory approvals and expanded strategic defence partnerships, positioning itself at the forefront of sovereign lithium sulfur battery supply.

Sparc Technologies launches a $2.5 million capital raise via a Share Purchase Plan and placement to fast-track commercial rollout of its graphene additive ecosparc® and support green hydrogen scale-up.

Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.

Energy Fuels Inc. reported a transformative 2024 with a major acquisition boosting its heavy mineral sands assets, a uranium production ramp-up at key US mines, and commercial rare earth oxide output from its White Mesa Mill.